Safety And Efficacy Of A Surgically Implanted Suprachoroidal Retinal Prosthesis (Bionic Eye)
Funder
National Health and Medical Research Council
Funding Amount
$1,233,826.00
Summary
A bionic eye is a electronic device which can stimulate the remaining visual pathway in a person who is blind, to restore some basic vision. Our team have previously shown that our novel bionic eye device can be safely implanted in a patient, and can give improvements in vision when tested in a laboratory environment. The next stage of the research is to provide patients with a more advanced device, which will contain more electrodes and also be able to be taken home.
High Penetrance Deleterious Mutations In Blinding Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$1,345,055.00
Summary
This project aims to identify the genes most commonly mutated in individuals with advanced glaucoma. Identification of such genes will lead to improved understanding of glaucoma pathogenesis, a better ability to predict risk, and the identification of drug targets for novel therapies.
Improving Visual Outcomes In Patients With Diabetic Macular Oedema Undergoing Cataract Surgery: A Prospective Randomised Clinical Trial (the DiMECat Trial)
Funder
National Health and Medical Research Council
Funding Amount
$187,322.00
Summary
Cataract and diabetic retinopathy are the leading causes of visual loss in patients with diabetes, but unfortunately, cataract surgery in these patients often results in a loss of vision, rather than an improvement. The purpose of this study is to improve the visual outcomes in this group of patients, through the use of new, injected medicines that are given at the time of cataract surgery, thereby potentially changing current medical practice.
Clinical Trial Of A Suprachoroidal Visual Prosthesis For The Profoundly Vision Impaired
Funder
National Health and Medical Research Council
Funding Amount
$1,098,802.00
Summary
For 15 years we have been designing a bionic eye. We have made a device called the Phoenix99 and shown in short term animal tests that it is both safe to implant but also that it potentially performs better than any other device in the world. We are requesting funds to complete longer term animal testing of the device and then commence a small human clinical trial to demonstrate the benefits of the technology – specifically that it is able to help blind people navigate without assistance.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
A Genome-wide Association Study In 2000 Glaucoma Cases With Matched Controls Using Equimoloar DNA Pools
Funder
National Health and Medical Research Council
Funding Amount
$610,267.00
Summary
Glaucoma is a common cause of loss of vision worldwide but we are unable to predict which people are at high risk of blindness. We aim to discover the genetic risk factors for glaucoma. We will use cutting edge genetic technology to assess the whole genome in thousands of patients with glaucoma. We hope to identify important new glaucoma genes, which could lead to the development of diagnostic tests and treatments which will provide the most cost-efficient ways to prevent glaucoma blindness.
Electrical Stimulation Of The Brain For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$1,555,864.00
Summary
This project is focused on the clinical demonstration of the Monash Vision Group’s ‘Gennaris’ cortical prosthesis or bionic eye. The clinical work will demonstrate the use of the Gennaris as a viable medical device that provides useful vision to people with adult-onset profound vision loss in their everyday living environments. This will place MVG in a position to attract funding from investors or commercial partners to perform multi-site clinical trials and obtain regulatory approval.
Identification And Characterisation Of Novel Genes For Congenital Cataract
Funder
National Health and Medical Research Council
Funding Amount
$432,750.00
Summary
Cataracts are the leading cause of blindness worldwide. The term describes a clouding of the lens which may lead to visual impairment. Congenital cataracts (present at birth) are less common than age-related cataract but the lifelong impact on vision can be severe, with a third of patients remaining legally blind. Late complications such as aphakic glaucoma may be blinding. We have shown that congenital cataracts are often inherited and have performed a population-based study in South-Eastern Au ....Cataracts are the leading cause of blindness worldwide. The term describes a clouding of the lens which may lead to visual impairment. Congenital cataracts (present at birth) are less common than age-related cataract but the lifelong impact on vision can be severe, with a third of patients remaining legally blind. Late complications such as aphakic glaucoma may be blinding. We have shown that congenital cataracts are often inherited and have performed a population-based study in South-Eastern Australia over the past 5 years to determine the causative genes. A large number of families have been involved in the study and solid progress has been made in identifying mutations in cataract genes and understanding what effect these may have on the patient's prognosis. We have recently identified a new gene in a large Australian family with a syndrome of cataract, mental retardation and teeth problems. This syndrome, known as Nance-Horan syndrome was originally described in Australia 30 years ago and we have worked with the original family to find the exact gene responsible. We already know that this gene causes the same syndrome in other families and in this project we will examine whether it can cause cataract without the other features or mental retardation without cataract. We will perform a series of experiments to learn what this gene does and how it causes the disease. We have also selected 3 other very interesting families with congenital cataracts for further study as we either know already or strongly suspect that they will enable us to identify further new genes for cataract, and in one case mental retardation. Our work in other diseases indicates that understanding the genes in severe young onset cases can give valuable clues to the causes of age-related forms and may in the future enable new ways to prevent and treat the commonest cause of worldwide blindness.Read moreRead less
Oxidative Phosphorylation Regulation And Neuroprotection In Optic Neuropathies
Funder
National Health and Medical Research Council
Funding Amount
$430,231.00
Summary
We have shown clear differences in the mitochodria, cellular organelles that generate energy, between optic atrophy patients who have good vision and those of patients who have poor vision. We believe that these changes represent a compensation mechanisms that preserves mitochondrial energy production and protects optic nerve cells. This study will characterize these differences further with the aim of identfying new treatments for preventing nerve loss and preserving vision.
Dissecting The Pseudoexfoliation Syndrome With Complementary Genetic, Proteomic And Biophysical Strategies
Funder
National Health and Medical Research Council
Funding Amount
$490,352.00
Summary
Pseudoexfoliation syndrome (PEX) is an eye condition in which flaky material deposits in the eye, greatly increasing the risk of cataract and glaucoma which can lead to blindness. PEX is also associated with heart disease, strokes and aneurysms. Cataract surgery in PEX patients has a higher rate of complications. In this project we will determine the nature of PEX material and why it forms. This knowlege will facilitate better diagnosis and treatment of PEX preventing associated blindness.